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Endometrial TGFβ1 and Heavy Menstrual Bleeding 
Context: Heavy menstrual bleeding (HMB) is common and incapacitating. Aberrant 
menstrual endometrial repair may result in HMB. The TGFβ superfamily contributes to tissue 
repair, but its role in HMB is unknown. Objective: We hypothesised that TGFβ1 is important 
for endometrial repair and women with HMB have aberrant TGFβ1 activity at menses. 
Participants/Setting: Endometrial biopsies were collected from women and menstrual blood 
loss objectively measured (HMB >80ml/cycle, normal menstrual bleeding, NMB <80ml). 
Design: Immunohistochemistry and RT-PCR examined endometrial TGFβ1 ligand, receptors 
and downstream SMADs in women with NMB and HMB. The function and regulation of 
TGFβ1 was examined using primary stromal cell culture. Results: TGFB1 mRNA was 
maximal immediately prior to menses, but no differences were observed between women 
with NMB and HMB at any cycle stage. Histoscoring of TGFB1 revealed reduced staining in 
the stromal compartment during menses in women with HMB (p<0.05). There were no 
significant differences in TGFBR1/2 or TGFBR1/2 immunostaining. Cortisol increased 
activation of TGFB1 in the supernatant of human endometrial stromal cells (HES, P<0.05) 
via thrombospondin-1. Endometrial SMAD2 and SMAD3 were lower in women with HMB 
during menstruation (P<0.05) and decreased phosphorylated SMAD2/3 immunostaining was 
seen in glandular epithelial cells during the late secretory phase (p<0.05). Wound scratch 
assays revealed increased repair in HES cells treated with TGFβ1 versus control (P>0.05). 
Conclusions: Women with HMB had decreased TGFβ1 and SMADs peri-menstrually. 
Cortisol activated latent TGFβ1 to enhance endometrial stromal cell repair. Decreased 
TGFβ1 activity may hinder repair of the denuded menstrual endometrium, resulting in HMB. 
PRECIS: TGFβ1 and downstream SMADs were decreased in perimenstural endometrium from 
women with heavy menstruation versus controls. TGFβ1 was activated by cortisol in endometrial cells 
and enhanced repair. 
Introduction 
The human endometrium is a complex and dynamic tissue.  Throughout the reproductive 
years of a woman’s life it responds to steroid hormones to prepare for implantation, shed its 
luminal portion in the absence of pregnancy and efficiently regenerate for the subsequent 
menstrual cycle.  Menstruation occurs as a result of the sharp decline in progesterone as the 
corpus luteum regresses.  This progesterone withdrawal stimulates an influx of inflammatory 
cells and release of matrix metalloproteinases, resulting in tissue destruction and menstrual 
bleeding (1,2).  
The regulation of endometrial repair after shedding remains undefined. Scanning electron 
microscopy and hysteroscopy analysis revealed that luminal epithelial cell migration 
precedes stromal expansion, but that breakdown and repair occur simultaneously in adjacent 
sections of the human endometrium during active bleeding (3).  Initiation of endometrial 
repair therefore occurs during the menstrual phase, when ovarian hormone levels remain low.  
Indeed, in the mouse model of simulated menstruation repair occurred without delay when 
both exogenous and endogenous estrogens were removed (4).  
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The transforming growth factor beta (TGFβ) superfamily includes TGFβs, activins, nodal 
and bone morphogenic proteins (BMPs).  This superfamily have been implicated in cell 
motility, proliferation, apoptosis, immune response and differentiation [reviewed in (5)].  
Therefore, they are attractive candidates for the co-ordination of endometrial repair at 
menses.  
TGFβ is synthesised as a dimeric pre-proprotein and is released in a latent form. It is 
activated in a tissue specific fashion by a variety of mechanisms, including extremes of pH or 
via plasmin or thrombospondin-1 (6,7).  Once activated, it binds to type II transmembrane 
serine/threonine kinase receptors, which then form a heterotetrameric complex with dimers of 
type I receptors.  This leads to phosphorylation and activation of intracellular regulatory 
SMADs (SMAD-2 and -3), which in turn interact with the co-mediator SMAD-4 and 
translocate to the nucleus to regulate transcription of target genes.  TGFβ ligands and 
receptors are present in the human endometrium with maximal levels found during 
menstruation (8).  TGFβ ligand expression was found to be suppressed by progesterone (8), 
meaning endometrial induction following progesterone withdrawal is expected.  Despite the 
low levels of circulating progesterone and estradiol at menses, local generation of steroids in 
the endometrium may play a vital role in menstrual physiology.  Endometrial expression of 
the enzyme 11βHSD1, necessary for local generation of cortisol, and the expression of the 
cortisol receptor GR have both been reported to be up-regulated at the time of menses (9).  
The role of cortisol in the regulation of TGFβ remains undetermined. 
Heavy menstrual bleeding of endometrial origin (HMB-E) is a common condition with a 
significant impact on the quality of life of otherwise healthy women (10).  The financial costs 
to women, their families and employers are marked (11).  HMB-E can be contributed, at least 
in part, to delayed or ineffective endometrial repair at menses.  Identification of the 
mechanisms involved in endometrial repair and aberrations in women with HMB-E will lead 
to new, effective medical therapies for the many women suffering from this debilitating 
condition. 
Herein we hypothesise that TGFβ1, its receptors and downstream SMADs are important 
for endometrial repair at menses and that women with HMB-E have aberrant expression of 
this superfamily prior to and during the menstrual phase.  To investigate this we used well-
categorised endometrial whole tissue biopsies from women with objectively measured 
normal (<80ml) and heavy (>80ml) menstrual blood loss alongside in vitro endometrial cell 
culture and functional assays.  
Materials and Methods 
Tissue collection 
Endometrial biopsies were collected with an endometrial suction curette (Pipelle, Laboratorie 
CCD, Paris, France) from 91 healthy women of reproductive age, who were predominantly 
White/Caucasian.  Written informed consent was obtained and ethical approval granted from 
Lothian Research Ethics Committee (LREC/07/S1103/29). Participants were aged 22 to 50 
years (median 41; mean 41).  All reported regular menstrual cycles (21 to 35 days) and had 
not taken any exogenous hormones or used an intrauterine device for 3 months prior to tissue 
collection.  Women with large fibroids (>3cm) and endometriosis were excluded.   
Immediately after collection tissue was divided when possible and placed in (i) RNA later 
stabilisation solution (Ambion (Europe) Ltd., Warrington, UK) and stored at -70ºC for RNA 
extraction, (ii) neutral buffered formalin (NBF) prior to paraffin wax embedding and (iii) 
phosphate buffered saline (PBS) for stromal cell extraction.  If limited tissue was obtained 
(which often occurred with menstrual phase collection), NBF fixation was prioritised. 
Menstrual stage was carefully categorised according to (i) histological appearance based 
on the criteria of Noyes et al. (12), assessed by a consultant pathologist (ii) the participant’s 
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reported last menstrual period (LMP) and (iii) serum progesterone and estradiol levels at the 
time of biopsy (see supplementary methods).  Consistency for all three parameters was 
necessary before inclusion. Six endometrial tissue samples were excluded due to inconsistent 
dating and one sample due to detection of hyperplasia. Biopsies were classified as 
proliferative (P), early-mid secretory (E-MS), late secretory (LS) or menstrual (M) for 
analysis (Supplementary Table 1).  
Objective menstrual blood loss measurement 
A subset of women (n=78) also had objective measurement of their menstrual blood loss 
(MBL) using the modified alkaline haematin method, as previously published (13,14).  In 
brief, women were given the same brand of tampon and/or pad (Tampax tampons and 
Always towels, Proctor and Gamble, UK), with verbal and written instruction on collection.  
Used sanitary products were added to a measured volume of 5% sodium hydroxide.  The 
contents were left for 24h to allow conversion of haemoglobin to haematin.  During the same 
time period, a 1 in 200 dilution of the patient’s venous blood in 5% sodium hydroxide was 
made and stored separately.  The optical density (OD) of the samples were then measured 
using spectrophotometry at 546nm (A546). MBL was calculated using the following equation 
(13): 
 
 
OD of menstrual blood solution total volume of added NaOH
MBL
OD of venous blood 200
 
 
Greater than 80ml was classified as heavy menstrual bleeding (HMB) and less than 80ml as 
normal (NMB).  
Immunohistochemistry 
5µm tissue sections were deparaffinised in xylene and rehydrated.  Slides for TGFβRI and II 
were loaded into a Celerus Riptide de-cloaking chamber (Celerus Diagnostics Carpinteria, 
CA , United States) epitope retrieval was performed using Novocastra Epitope Retrieval 
solution Ph6 (Leica Microsystems GmbH, Ernst-Leitz-Straße, Wetzlar, Germany).  Slides 
were loaded onto Leica Bond-Max automated immunostainer (Leica Microsystems GmbH, 
Ernst-Leitz-Straße, Wetzlar, Germany).  Primary antibodies were applied for 2h at 37°C (see 
supplementary Table 2) and negative control tissues incubated with isotype-matched IgG at 
the same concentration as the primary antibody.  The presence of antigen was visualised with 
Bond Polymer refine detection kit (Leica Microsystems GmbH, Ernst-Leitz-Straße, Wetzlar, 
Germany). TGFβ1 detection was performed on the laboratory bench after pH9 antigen 
retrieval.  The ImmPRESS polymerised reporter system (Vector Laboratories) was utilised 
before liquid diaminobenzidine (DAB) kit (Zymed Laboratories, San Francisco, CA, USA) 
detection. Sections were counterstained with haematoxylin, dehydrated and mounted with 
Pertex (Cellpath plc, Hemel Hempstead, UK). 
Semi-quantitive histoscoring 
Localisation and intensity of immunostaining was evaluated by two independent, masked 
observers (15).  The intensity of staining was graded with a three-point scale (0 = no staining, 
1 = mild staining, 2 = strong staining).  This was applied to the glands and stromal cells, as 
well as the surface epithelium and endothelial cells where visualised (N.B. the latter two 
cellular components were often absent in menstrual phase tissue, accounting for the lower n-
numbers in these groups).  The percentage of tissue in each intensity scale was recorded (15).  
A value was derived for each of the cellular compartments by using the sum of these 
percentages after multiplication by the intensity of staining.  
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Cell culture 
Primary human endometrial stromal (HES) cells were isolated from secretory endometrial 
tissue (n=6) by enzymatic digestion as previously described (16).  These women met the 
criteria detailed above in “tissue collection” but did not undergo objective measurement of 
their menstrual blood loss.  Cells were cultured in Roswell Park Memorial Institute (RPMI) 
1640 medium supplemented with 10% FCS, 1% 200mM L-Glutamine and 500mg/ml 
Gentamycin.  
Secretory phase HES cells from three patients with a subjective complaint of HMB and 
not using oral or inhaled corticosteroids were plated at 3x105 cells per well in 6 well plates in 
10% RPMI 1640.  The next day, cells were washed in PBS and incubated in serum free 
media overnight. Cells were then treated for 24h in duplicate with (i) vehicle (1:1000 ETOH), 
(ii) 1μM cortisol (17) or (iii) 1μM cortisol plus 5μM LSKL, a TSP-1 inhibitor (following a 2h 
pre-treatment with 5uM LSKL alone).  The cell supernatant was collected for ELISA and 
RNA extracted from cells. 
Q RT PCR 
Total RNA from cells and endometrial biopsies was extracted using the RNeasey Mini Kit 
(Qiagen Ltd, Sussex, UK) with on column DNaseI digestion according to manufacturer’s 
instructions.  RNA samples were reverse transcribed using the Superscript VILO cDNA 
synthesis kit (InVitrogen, Paisley, UK) according to manufacturer’s instruction with 
appropriate controls.  Primers for each gene of interest were designed using the Universal 
Probe Library Assay Design Center (Roche Applied Science, Burgess Hill, UK) (see 
supplementary Table 3) and purchased from Eurofins (MGW Operon, Ebergsberg, 
Germany). PCR was carried out using ABI Prism 7900 (Applied Biosystems).  Samples and 
controls were analysed in triplicate using Sequence Detector version 2.3 (PE Biosystems), 
using the comparative threshold method. Messenger RNA transcripts were normalised 
relative to the geomean of two appropriate housekeeping genes 18S and ATP5B as 
determined by geNorm assay (Primerdesign Ltd., Southampton, UK) and quantified relative 
to a positive human liver cDNA sample.  
ELISA 
A TGF-β1 ELISA was performed using a Human TGF-β1 Quantikine Kit (DB100B; R&D 
Systems) according to the manufacturer's instructions.  Samples were analysed without 
activation and with latent TGF-β1 activated to the immunoreactive form using 1m HCl and 
neutralized with 1.2m NaOH/0.5m HEPES buffer.  Samples were assayed in duplicate, and 
after development assays were measured on a Lab Systems Multiscan EX Microplate reader 
at 450nm with wavelength correction at 540nm.  Values were determined by standard curve 
analysis. Intra-assay CV was 2.5%, and the between-batch CV was 8.3% for cell culture 
supernatants. 
Wound scratch assay 
Secretory phase HES from three participants (passage <5) were seeded at 2 × 105 per well in 
12 well plates in appropriate supplemented media (see above) and 16h before scratch, 
medium was changed to serum-free.  Each well of cells was scratched with a sterile 200μl 
pipette tip, washed with PBS and then incubated in serum free media with vehicle, 1ng 
human recombinant TGFβ1 (Peprotech, London, UK) or 10μg/ml of the TGFβ type I activin 
receptor-like kinase (ALK) receptors inhibitor SB 431542 hydrate (Sigma Aldridge, Dorset, 
UK) (n = 3 participants, triplicate wells for each).  For each well, 4-5 images were captured 
along the length of each wound at 0 and 24h using an Axiovert 200M inverted microscope 
(Carl Zeiss, Jena, Germany).  Images were analyzed using AxioVision release 4.72, and 
calculations of average distance closed for each sample were based on three measurements at 
identical positions along each wound image at 0 and 24h. 
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Statistical Analysis 
Analysis was carried out using GraphPad Prism Software, Inc., San Diego, CA.  For 
comparison of multiple data sets with two grouping variables (i.e. HMB vs NMB and stage of 
menstrual cycle, mRNA and immunohistochemistry data) a two way ANOVA was utilised, 
with Bonferroni’s multiple comparisons test. A paired one way ANOVA with Tukey’s 
multiple comparisons test was used to compare cell culture treatments. Tissue and cell 
endometrial mRNA results were expressed as the quantity relative to a comparator sample of 
RNA from human liver. A value of P<0.05 was considered significant. 
Results 
There is increased transcription of TGFB1 in the late secretory phase 
TGFβ1 mRNA was examined by qRT PCR in whole endometrial biopsies from women 
sampled at various stages of the menstrual cycle who had objectively determined menstrual 
blood loss.  Overall the stage of the menstrual cycle had a significant impact on TGFB1 
expression (P=0.0025, F=5.339), with the late secretory phase resulting in significantly 
higher levels of TGFB1 than endometrium from the proliferative (p<0.001) or early-mid 
secretory (p<0.01) phases (Figure 1). There was no significant difference between the late 
secretory and menstrual phase.  The increased transcription of TGFB1 in the late secretory 
phase did not continue into the menstrual phase.  
Women with HMB do not have altered endometrial TGFB1 transcription or TGFβ1 reception 
We compared the expression of TGFB1 in women with NMB and HMB (Figure 1) and found 
no significant difference in TGFB1 expression between the two groups at any cycle stage.  In 
addition the two major TGFβ1 receptors, type I and type II, were examined in the late 
secretory and menstrual endometrial samples.  Neither TGFBR1 nor TGFBR2 expression was 
significantly different in endometrium from women with HMB versus NMB (Figure 2A,B).  
Immunohistochemical staining revealed maximal staining of TGFBR1 in surface and 
glandular epithelial cells, with lower intensity staining in the stromal compartment (Figure 
2C).  TGFBR2 showed a similar pattern, with highest immunostaining in epithelial and 
endothelial cells (Figure 2D).  Semi-quantitative histoscoring by two masked independent 
observers confirmed no differences in either receptor when comparing women with HMB 
and NMB throughout the perimenstrual phase (Figure 2E,F).  
Women with HMB have reduced perimenstrual endometrial stromal TGFB1 
As the numerous cell types in the endometrium differentially expressed TGFβ1 receptors, we 
examined the localisation of TGFB1 by immunohistochemistry.  TGFB1 could be 
immunolocalized to the cytoplasm of the surface epithelium, glandular epithelium, stromal 
cells and endothelial cells throughout the perimenstrual phase of the cycle in women with 
NMB (<80ml) and HMB (>80ml) (Figure 3A).  Semi quantitative histoscoring revealed that 
protein in the menstrual phase was similar to late secretory phase. There was significantly 
reduced TGFB1 staining in the stromal cell compartment of endometrium from women with 
HMB versus those with NMB (Figure 3B).  This suggests some post transcriptional 
regulation of TGFβ1 in stromal cells.  
Cortisol increases stromal TGFβ1 activity via thrombospondin-1 
To further investigate the post-transcriptional regulation of TGFβ1 we collected primary HES 
cells from three women in the secretory phase of the menstrual cycle for in vitro analysis. 
Peri-menstrual serum progesterone and estradiol levels were not significantly different 
between women with HMB or NMB (Supplementary Table 1). However, we have previously 
shown that cortisol is involved both in endometrial repair and the regulation of endometrial 
thrombospondin-1 (TSP-1) (14), a known regulator of TGFβ1 activity (6).  Cortisol or 
cortisol plus LSKL (a TSP-1 inhibitor) produced a significant decrease in TGFB1 expression 
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in HES cells (p<0.05, Figure 4A) but there was no difference in the amount of latent TGFB1 
secreted, detected by pH activation of culture supernatants prior to detection of activated 
TGFB1 by ELISA (Figure 4B).  However analysis of unactivated cell culture supernatants 
revealed an increase in activation of TGFβ1 protein on treatment with cortisol, which was 
prevented with co-treatment of cells with the TSP-1 inhibitor LSKL (p>0.05, Figure 4C).  
These data reveal cortisol does not increase the transcription or latent protein levels of 
stromal cell TGF-β1 but has a role in the activation of latent TGF-β1 in human endometrial 
stromal cells, via TSP-1. 
Women with HMB have reduced perimenstrual endometrial SMAD 2/3  
TGFβ1 activity increases the expression and phosphorylation of the regulatory SMADs 
(SMAD2 and SMAD3).  These activated pSMADs then interact with the co-mediator 
SMAD-4 and translocate to the nucleus to regulate transcription of target genes (5).  
Examination of SMAD2 and SMAD3 expression revealed significant decreases in women 
with HMB versus NMB during the menstrual phase of the cycle (P<0.05, Figures 5A,B).  
SMAD2 was significantly increased in women with HMB versus NMB during the late 
secretory phase. (Figure 5A).  Immunohistochemical staining for phosphorylated SMAD 2/3 
again revealed localisation to the glandular epithelium, surface epithelial cells, stromal 
compartment and endothelial cells (Figure 5C,D).  Histoscoring revealed a significant 
reduction in activated SMAD 2/3 protein levels in the endometrial glandular epithelial cells 
in women with HMB versus NMB during the late secretory phase of the menstrual cycle 
(Figure 5D).  
TGFβ1 accelerates wound healing in primary endometrial cells  
To examine the functional effects of increased TGFβ1 activity, primary HES were subjected 
to a wound scratch assay.  As these cells are sources of TGFβ1 they were studied in the 
presence of vehicle, SB-431542 (to block endogenously stimulated phosphorylation of 
SMAD proteins ) or TGFβ1. HES cells showed significantly increased wound closure with 
TGFβ1 treatment versus SB-431542 treated cells (p<0.05, Figure 6A,B).  
Discussion 
Herein we detail significant differences in TGFβ1 downstream of local steroid action in the 
endometrium of women with HMB during menstruation.  Endometrium from women with 
objectively measured HMB had decreased TGFβ1 protein levels, unaltered TGFβ receptor 
presence and a significant reduction in both SMAD2 and -3 mRNA expression and SMAD 
2/3 protein phosphorylation before/during the menstrual phase when compared to women 
with NMB.  We provide mechanistic data supporting TGFβ1 protein activation by cortisol in 
endometrial cells, via thrombospondin-1.  In addition, our functional studies reveal that a 
suboptimal TGFβ response in the local endometrial environment may decrease post-
menstrual repair of the stromal compartment and lead to heavy, prolonged menstrual bleeding 
(Figure 7). 
Previous studies have detailed that TGFβ1 levels in endometrial tissue explants are 
suppressed by progesterone (8).  These authors found secretory explants cultured for 24h in 
the absence of progesterone and estrogen, a milieu analogous to the menstrual phase, 
significantly increased TGFβ1 mRNA.  Our results support these findings, with significantly 
greater TGFβ1 mRNA prior to and during menstruation when compared to the proliferative 
and early-mid secretory phases, consistent with up-regulation following progesterone 
withdrawal.  We did not observe any significant difference in endometrial TGFβ1 mRNA 
between women with HMB and normal blood loss during menstruation, although we 
acknowledge our n-numbers are small.  However, we did observe significantly decreased 
TGFβ protein in the stromal compartment of women with HMB versus NMB during 
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menstruation. We acknowledge that menstrual biopsy n-numbers are low but these tissues are 
meticulously classified and have objective measurement of participant menstrual blood loss 
to aid precision of data. Our results suggest differences in TGFβ1 protein in women with 
HMB and NMB are not due to transcriptional regulation, but that post-transcriptional 
regulation may be aberrant. 
Interestingly, there were no significant differences in serum progesterone or estradiol 
levels between women with HMB and NMB. In addition, no significant differences in 
endometrial estradiol receptor or progesterone receptor expression were previously detected 
in women with measured menstrual blood loss (18). Therefore, we hypothesised that local 
cortisol action may influence TGFβ1 activity during menses.  
TGFβ is synthesised as a dimeric pre-proprotein and is released in a latent form.  
Thrombospondin-1 (TSP-1) is known to activate TGFβ1 and is thought to do so by inducing 
a conformational change in the latent protein (6).  Our laboratory has previously published 
that women with HMB have significantly reduced endometrial TSP-1 mRNA levels when 
compared to women with normal bleeding (14).  Previous studies from our laboratory have 
also found that cortisol increases TSP-1 mRNA expression in primary human endometrial 
stromal cells (14).  Direct measurement of cortisol levels in the endometrium of women with 
HMB and NMB has not yet been carried out, but an enhanced local inactivation of cortisol by 
11βHSD2 may be present in the endometrium of women with heavy menses (14). 11βHSD2 
mRNA was increased 2.5 fold in women with HMB versus NMB, predicting substantially 
lower local cortisol concentrations.  Therefore, we examined if cortisol was a local regulator 
of TGFβ1 activity via TSP-1. On examination of cell culture supernatants from HES cells 
treated with physiological levels of cortisol (17), activated TGFβ1 was significantly 
increased.  This increase was abrogated by the addition of a TSP-1 inhibitor to culture. 
Interestingly, acid activation of latent TGFβ1 in the culture supernatant prior to ELISA 
resulted in no differences in TGFβ1 levels with any of the treatments used.  This is consistent 
with cortisol stimulated TSP-1 production acting on latent TGFβ1 protein to increase its 
activity, rather than increasing the transcription or translation of TGFβ1.  Indeed, cortisol and 
cortisol plus TSP-1 inhibitor treatment both significantly decreased TGFβ1. TGFβ1 mRNA 
was not significantly different in the endometrium of women with NMB versus HMB during 
the peri-menstrual phase, but there was a trend towards increased TGFβ1 mRNA 
concentrations in women with HMB at this time, consistent with lower endometrial cortisol 
levels (14).  
Next we examined the functional significance of TGFβ1 protein levels on endometrial 
cells. After shedding, endometrial cells migrate to cover the exposed surface of the 
endometrium and the stromal compartment regenerates (19).  The wound scratch assay 
mimics this process in vitro, providing a means of quantifying stromal cell migration across a 
wounded surface.  We found that TGFβ1 increased wound healing of primary stromal cell 
cultures.  As we detected reduced phosphorylation of SMAD 2/3 in the endometrium of 
women with HMB versus NMB, we blocked TGF-β-mediated activation of SMAD proteins 
with SB 431542 and showed a decrease in stromal cell wound migration, which was 
significantly less that that seen with the addition of TGFβ1.  We propose that women with 
HMB may have defective or delayed repair of the stromal cell compartment following 
shedding of their functional endometrium at menses. 
In addition to its functional role in proliferation, it is clear that the TGFβ superfamily play 
an important role in endothelial cell function and blood loss.  Greater than 50% of TGFβ1 
knockout mice die during embryogenesis due to yolk sac defects affecting vasculogenesis 
and resulting in vessel fragility (20).  In humans, mutation of the TGFβ receptor I ALKI or of 
the endothelial accessory receptor endoglin causes hereditary haemorrhagic telangiectasia 
(HHT), an autosomal dominant vascular disease (21).  The resulting aberrant TGFβ 
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superfamily signalling results in epistaxis, telangiectasia and arteriovenous malformations.  
Interestingly, previous histochemical and microscopic examination of endometrial blood 
vessels from women with normal and heavy menstrual bleeding revealed increased 
endothelial gaps in women with heavy loss (22).  The role of the TGFβ superfamily in this 
pathology remains to be determined, but the observational data contained herein suggest that 
low late secretory/menstrual TGFβ1 protein levels and decreased pSMAD 2/3 may be 
involved. Previous results from our centre support a role for TGFβ1 in the generation of 
vasoactive factors in in women with endometriosis (23,24) and it may have a similar, if more 
regulated, role in the endometrium to ensure physiological menstruation.  
We have previously shown that cortisol is angiostatic, preventing endothelial tube-like 
structure formation in vitro (14).  Furthermore, SiRNA silencing of TSP-1 in uterine 
endothelial cells reversed the anti-angiogenic effect.  In combination with data contained 
herein, we propose that cortisol may activate endometrial TGFβ1 via TSP-1 during menses to 
prevent an excessive angiogenic response and increase vascular integrity.  Further 
experiments are required to definitively test this hypothesis.  
In conclusion, we show that women with objectively measured HMB have decreased 
endometrial TGFβ1 protein and downstream SMADs during the late secretory/menstrual 
phase when compared to women with NMB.  This may partially explain the increased 
menstrual blood loss experienced by many women. In addition, we show that cortisol has a 
mechanistic role in the activation of endometrial TGFβ1 at this time (Figure 7).  Our in vitro 
results are consistent with TGFβ1 having a functional role in repair of the denuded 
endometrial surface at menstruation and we propose that women with HMB may benefit from 
therapies that increase TGFβ during menses.  
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Figure 1. TGFB1 in the human endometrium. TGFβ1 mRNA expression in endometrium 
from across the menstrual cycle in women with HMB (blood loss >80ml) and NMB (blood 
loss <80ml). P proliferative, E/MS early-mid secretory, LS late secretory, M menstrual. 
***P<0.001, **P<0.01.  
Figure 2. TGFβRI and TGFβRII in the human endometrium before and during 
menstruation. (A) TGFβRI mRNA expression in endometrium from women with normal 
(NMB; <80ml) and heavy (HMB; >80ml) menstrual bleeding during the late secretory (LS) 
and menstrual (M) phases (B) TGFβRII mRNA expression (C) Immunohistochemical 
staining of TGFβRI in endometrium from the late secretory phase. SE: surface epithelium, 
GE: glandular epithelium, St: stromal cell compartment, arrow: endothelial cells (D) 
Immunohistochemical staining of TGFβRII in endometrium from the late secretory phase, 
inset: negative control (E) Immunohistochemical histoscore of TGFβRI in human 
endometrium from women with heavy and normal bleeding during the late secretory and 
menstrual phases (F) Immunohistochemical histoscore of TGFβRII in human endometrium 
from women with heavy and normal bleeding during the late secretory and menstrual phases. 
(N.B. lower n-numbers appear in SE and endothelial cell scoring due to the inability to 
identify these cells in some tissues). 
Figure 3. Immunohistochemistry for TGFβ1 in human endometrium from the 
perimenstrual phase. (A) Staining of late secretory and menstrual phase endometrium from 
women with HMB (>80ml) and NMB (<80ml). GE glandular epithelium, SE surface 
epithelium, St stromal compartment, arrows indicate endothelial cells. Inset: negative control 
(B) Semi quantitative histoscoring of TGFβ1 immunohistochemistry staining.  
Figure 4. The regulation of TGFβ1 by cortisol in primary human endometrial stromal 
cells. (A) TGFβ1 mRNA after 24h treatment with vehicle, cortisol (1μM) or cortisol (1μM) 
plus a thrombospondin-1 inhibitor (LSKL 5μM) (B) Active TGFβ1 protein levels in 
experimental culture supernatants following pre-ELISA acid activation of latent TGFβ1 (C). 
Active TGFβ1 protein levels in the same culture supernatants without pre-ELISA acid 
activation. (*P<0.05). 
Figure 5. SMAD2/3 in the human endometrium before and during menstruation. (A) 
SMAD2 mRNA expression in endometrium from women with normal (NMB; <80ml) and 
heavy (HMB; >80ml) menstrual bleeding during the late secretory (LS) and menstrual (M) 
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phases (B) SMAD3 mRNA expression in endometrium from women with NMB and HMB in 
the LS and M phases (C) Phosphorylated SMAD2/3 immunohistochemical staining in late 
secretory endometrium from a woman with NMB. Inset: negative control. SE: surface 
epithelium, GE: glandular epithelium, St: stromal cell compartment, arrow: endothelial cells 
(D) Phosphorylated SMAD2/3 immunohistochemical staining in late secretory endometrium 
from a woman with HMB (E) Histoscoring of immunostaining for phosphorylated 
SMAD2/3. *P<0.05. 
Figure 6. The effect of TGFβ1 on human endometrial cell wound repair. (A) Average 
wound scratch closure distance (scratch distance at 0h minus scratch distance at 24h) in 
human primary stromal endometrial cells after treatment with vehicle, the Alk receptor 
inhibitor SB431542 or 1ng TGFβ1. (B) Images of wound scratch in HES cells treated with 
10μg/ml SB431542 for (i) 0h (ii) 24h and treated with 1ng TGFβ1 (iii) 0h and (iv) 24h. 
Figure 7. Proposed role of TGFβ1 in the human endometrium at menstruation. Red 
stars represent findings in women with HMB and potential impact on endometrial function. 
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